FLOW and SGLT2 inhibitors in CKD

The FLOW trial established that once-weekly semaglutide reduced a composite of major kidney disease events in people with type 2 diabetes and chronic kidney disease. A 2026 review asks the next question: how should that result be positioned beside the established kidney benefits of SGLT2 inhibitors? Its answer is mechanistic complementarity, not proof that combining the two classes produces additive clinical benefit^[1][2].

What FLOW tested

FLOW randomly assigned 3,533 participants with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg weekly or placebo. The primary outcome combined kidney failure, a sustained reduction of at least 50% in estimated glomerular filtration rate, and death from kidney-related or cardiovascular causes^[2]. The trial was stopped early after a prespecified interim analysis, and median follow-up was 3.4 years.

A primary-outcome event occurred 331 times in the semaglutide group and 410 times in the placebo group. The hazard ratio was 0.76, with a 95% confidence interval from 0.66 to 0.88. The kidney-specific components also favored semaglutide. Cardiovascular death and major cardiovascular events favored semaglutide, as did all-cause death^[2]. Serious adverse events were recorded in 49.6% and 53.8% of participants, respectively.

What SGLT2 outcome trials had already shown

SGLT2 inhibitors reached the CKD outcomes field earlier. EMPA-KIDNEY enrolled 6,609 people with chronic kidney disease across a broad range of kidney function. Empagliflozin reduced the composite of kidney disease progression or cardiovascular death compared with placebo: 13.1% versus 16.9%, corresponding to a hazard ratio of 0.72 over a median two years^[3]. The result was consistent in participants with and without diabetes.

DAPA-CKD randomized 4,304 participants with chronic kidney disease to dapagliflozin or placebo. The primary composite occurred in 9.2% and 14.5%, respectively, over a median 2.4 years. The hazard ratio was 0.61, and the reported number needed to treat over the trial period was 19^[4]. Effects were similar whether or not participants had type 2 diabetes.

These trials cannot be ranked by comparing hazard ratios alone. They enrolled different populations, used different outcome definitions, and followed participants for different periods. FLOW required type 2 diabetes and albuminuric CKD. EMPA-KIDNEY and DAPA-CKD included participants without diabetes. A smaller hazard ratio in one trial does not prove that its drug class is better for an individual patient.

Why the mechanisms may complement each other

The 2026 review describes SGLT2 inhibition mainly as proximal tubular and hemodynamic offloading. By reducing sodium and glucose reabsorption in the proximal tubule, the class changes delivery to the macula densa and affects intraglomerular pressure. The authors also discuss metabolic reprogramming and oxygen-stress balance. Autophagy and cellular housekeeping are other possible contributors^[1]. These mechanistic claims draw on experimental and translational evidence. They are not all separately proven mediators of the outcome-trial benefit.

The review positions GLP-1 receptor agonists differently. It emphasizes changes in inflammation and endothelial integrity, along with fibrotic signaling. The proposed overlap between the classes includes mitochondrial function and autophagy, as well as barrier stability^[1]. This framework is useful because it gives researchers testable pathways. It should not be mistaken for a validated prescribing sequence.

What combination evidence exists

A 2024 mouse experiment provides preclinical support for an additive hypothesis. Researchers treated uninephrectomized diabetic db/db mice with empagliflozin, semaglutide, or both on top of ramipril for eight weeks. The triple regimen reduced expression of two proinflammatory and profibrotic genes, and the combined empagliflozin and semaglutide regimen produced larger changes in cardiac hypertrophy and fibrosis than either alone in that model^[5].

Mouse results are not kidney-outcome evidence in humans. The model used surgery, a specific diabetic strain, and background renin-angiotensin-system blockade. It can help select biomarkers and mechanisms for human studies, but it cannot establish that a person will gain additive protection or define the balance of benefits and adverse effects.

The evidence gap is a direct combination trial

FLOW showed semaglutide benefit against placebo on top of standard care. It was not designed as a randomized comparison of semaglutide plus an SGLT2 inhibitor versus either class alone. Background use of an SGLT2 inhibitor may support subgroup analyses, but a subgroup does not recreate randomized assignment to the combination. Treatment selection can be related to kidney function, prior tolerance, access, and clinician judgment.

A definitive combination study would need a prespecified clinical outcome, enough participants to detect an interaction, and follow-up long enough to observe kidney failure or sustained loss of function. It would also need to distinguish a truly additive effect from overlapping benefit delivered through different pathways. Mechanistic endpoints such as albuminuria, filtration slope, inflammatory markers, or imaging may explain a signal, but they do not replace hard outcomes.

How to read the translational position

The strongest clinical result is straightforward: FLOW moved semaglutide from exploratory kidney signals to a dedicated outcomes trial in type 2 diabetes with CKD. SGLT2 inhibitors already had dedicated CKD outcome evidence extending beyond diabetes. The translational review offers a coherent reason to study the classes together, while explicitly rejecting a fixed algorithm based on mechanisms alone.

That distinction matters for readers following semaglutide evidence and regulation. Trial assignments describe research, not instructions. Kidney function, albuminuria, cardiovascular history, current medicines, tolerability, and labeled indications all affect clinical decisions. Starting or combining prescription medicines requires qualified clinical supervision.

What we do not yet know

It remains uncertain how much of FLOW's kidney benefit is shared across all GLP-1 receptor agonists. We also do not know whether combining a GLP-1 receptor agonist with an SGLT2 inhibitor produces additive hard-outcome benefit across CKD phenotypes, or which patients would gain the most. Future trials need to test those questions directly rather than infer an answer from separate placebo-controlled programs.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.